Navigating the Covid Confusion ~> The FDA’s Big Fat Hydroxychloroquine Blunder

Navigating the Covid Confusion

The blunder is in this comment from the FDA’s revocation of its EUA for hydroxychloroquine:

Hospitalized patients were likely to have greater prospect of benefit (compared to ambulatory patients with mild illness) and could be more closely monitored for potential toxicity, although it was recognized that enrollment in a clinical trial would be the best option when using these drugs so that data on safety and effectiveness could be obtained.

Hospitalized patients had likely already cleared the virus by the time they were hospitalized. This was known at the time of the EUA revocation. So giving antivirals after the virus had already been cleared was kind of…pointless. So the FDA knew that giving hydroxychloroquine to hospitalized patients wasn’t going to help them, barring some miraculous method of action. However, that wasn’t the biggest blunder.

To find the blunder, we have to look at the history of hospitalized patients. Most…

View original post 514 more words

About michael burgwin

A child of the peace and antiWar movements, a Truther with self-diagnosed Opposition Defiance Disorder, formerly politically liberal tho now politically marooned, and Post-Doomer, on any issue, I trend to the conspiracy side, sort through the absurd, fantastical and insane, until I find firm ground usually located just the other side of the censorship firewall of propaganda and orthodoxy, dogma, and other either / or thinking.
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s